louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04427059: A Study to Compare Two Techniques for Pain Control After Bariatric Surgery
Official title: Laparoscopic Assisted Transversus Abdominis Plane (TAP) Block Vs Local Anesthetic Infiltrations in Bariatric Surgery: a Prospective Randomized Double-Blind Controlled Trial (TAP BLOCK BARIATRIC TRIAL)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Postoperative
Bariatric Surgery Candidate
Keywords: Transversus Abdominis Plane (TAP) Block
Local Anesthetic Infiltrations
Lead sponsor: Ente Ospedaliero Cantonale, Bellinzona
Sponsor class: OTHER
First posted: 2020-06-11
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the postoperative pain and other clinical outcomes in patients who, during bariatric surgery, will be injected with a local anesthetic (Ropivacaine) through two different techniques.


Eligibility criteria: Inclusion Criteria:

* patients undergoing elective bariatric surgery
* age ≥ 18 years
* signed informed consent

Exclusion Criteria:

* Pregnant or lactating women,
* known allergy to local anesthetics
* Chronic pain syndrome.

Primary outcomes:
measure: Postoperative Pain
timeFrame: at 24 hours post surgery
Secondary outcomes:
measure: postoperative pain
timeFrame: at 3, 6, 12, 18 hours from surgery
measure: Number of Participants With Ropivacaine-Related Adverse Events
timeFrame: from surgery up to six weeks after surgery
measure: Number of participants with complications
timeFrame: from surgery up to six weeks after surgery
measure: lenght of hospital stay
timeFrame: during hospitalization,approximately 4 days
measure: in hospital satisfaction
timeFrame: during hospitalization,approximately 4 days
Other outcomes:
Locations:
city: Lugano
country: Switzerland
facility: Ospedale Regionale di Lugano, Civico e Italiano
Study officials:
affiliation: EOC Surgeery Department
name: Fabio Garofalo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06518759: Effect of Glossopharyngeal Versus Diaphragmatic Breathing Exercise on Pulmonary Function After Decortication Surgery
Official title: Effect of Glossopharyngeal Versus Diaphragmatic Breathing Exercise on Pulmonary Function After Decortication Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pulmonary Disease
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-07-24
Enrollment: 60
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be conducted to compare between the effect of glossopharyngeal and diaphragmatic breathing exercises on pulmonary functions after decortication surgery

Detailed description: Lung decortication is a well-known procedure for the treatment of empyema. Persistent lung collapse and non-expansion of the lung parenchyma are frequently noticed in the postoperative period after decortications, chest physiotherapy plays a crucial role in the re-expansion of underlying parenchyma.

There is an increased flow of patients after decortication surgery to hospitals who suffer from decreased lung volumes so the hospitalization period for them increases which puts an economical burden on health insurance services with a decreased level of quality of life that is the most concern to improve patient status and relieve this burden. So this study aims to improve patient's lung volumes and arterial blood gas parameters which improves patient status through two various forms of breathing exercises.

Eligibility criteria: Inclusion Criteria:

* The participant's body mass index (BMI) will be ranged from 25- 29.9 kg/m2
* The patient will receive treatment after 24 hours after decortication
* The study will be in the intensive care unit (ICU).
* The patients have unilateral lung decortication
* Their vital capacity is 70% or less.

Exclusion Criteria:

* Cancerous patient.
* Inability to comprehend and follow instructions as in dementia
* paralytic involvement of thorax muscle
* Abdominal diseases that affect diaphragmatic function
* Diaphragmatic paralysis

Primary outcomes:
measure: Tidal volume
timeFrame: within 2 weeks
measure: Inspiratory reserve volume (IRV)
timeFrame: within 2 weeks
measure: Expiratory reserve volume (ERV)
timeFrame: within 2 weeks
measure: Measurement of the potential of hydrogen (PH)
timeFrame: within 2 weeks
measure: Measurement of the partial arterial pressure of carbon dioxide(PaCO2)
timeFrame: within 2 weeks
measure: Measurement of the partial arterial pressure of oxygen (PaO2)
timeFrame: within 2 weeks
measure: Measurement of the Bicarbonate (HCO3)
timeFrame: within 2 weeks
measure: Measurement of oxygen saturation (SO2)
timeFrame: within 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Mai Gamal El-Din Mostafa
Study officials:
affiliation: Cairo University
name: Nesreen El-Nahas, professor
role: STUDY_CHAIR
References:
Clinical trial NCT00308659: Study to Evaluate Two Diagnostic Strategies for the Treatment of Severe Community Acquired Pneumonia (SCAP)
Official title: Diagnostic Strategy Evaluation Study of Two Diagnostic Strategies for the Treatment of SCAP : Noninvasive Strategy and Semiinvasive Strategy Including FOB Distal Samplings
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Community Aquired Pneumonia
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2006-03-30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Main hypothesis: microbiological diagnossis off severe community acquired pneumonia can be performed by non invasive or semi invasive microbiological tools, semi invasive tools including protected distal bronchial samplings by the mean of Fiber optic bronchoscopy (FOB). A microbiological diagnosis could improve antibiotic therapy efficacy and improve patient's outcome.

These Two strategies have never been prospectivally evauated.

* Aim of the study: To evaluate 2 diagnostic strategies: non invasive or semi invasive including protected distal bronchial samplings by the mean of Fiber optic bronchoscopy (FOB)for the care of patients admitted in intensive care for severe community acquired pneumonia and receiving an empirical antibiotic therapy as recommanded by 2001 American thoracic guidelines
* Type of study randomized multicentric controlled open study

Detailed description: Type of study randomized multicentric controlled open study

Number of patients: 200 patients (100 patients in each group)admitted in ICU for SCAP

* Number of center : 5
* Clinical strategies under evaluation :
* Group A: semi-invasive strategy: FOB within 24 hours after ICU admission
* Group B: non-invasive strategy: no FOB within 24 hours after ICU admission
* Evaluation criteria:

Main criteria: Changes in initial empirical antibiotic treatment according to microbiological results obtained in each group.

others

* FOB related complications
* Microbiological results
* Type of antibiotic treatment modifications
* ICU outcome and outcome at day 28
* Duration of antibiotic therapy and nimber of days without antibiotics at day 28 after inclusion

Eligibility criteria: Inclusion Criteria:

New radiological infiltrate SCAP clinical diagnosis admitted in ICU Admitted in hospital for less than 24 hours Aged 18 or older Signed informed consent

Exclusion Criteria:

Pregnancy Muribond patients Previuos hospitalisation within One month Neutropenia None HIV status

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Hotel dieu
Study officials:
affiliation: APHP
name: RABBAT Antoine, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01639859: Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci
Official title: Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer of Prostate
Keywords: prostate cancer
elastography
elasticity
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2012-07-13
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The primary aim of the study is to assess the elasticity (Young's modulus) of cancerous tumor foci, of normal peripheral zone, and of normal transition zone in the prostate. Images obtained with the Supersonic Imagine Aixplorer scanner prior to radical prostatectomy are compared to whole-mount histology.


Eligibility criteria: Inclusion Criteria:

* Patient over 18 years old, with prostate cancer and scheduled for radical prostatectomy

Exclusion Criteria:

* Medical history of prostate surgery or radiotherapy of prostate
* Medical history of abdominal perinéanal amputation or whole of state which prevent to use endorectal probe

Primary outcomes:
measure: Young's modulus(kPa) of cancerous tumor foci
timeFrame: 2 years
measure: Young's modulus(kPa) of normal peripheral zone
timeFrame: 2 years
measure: Young's modulus(kPa) of normal transition zone
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Service de Radiologie, Pavillon P Radio, Hôpital Edouard Herriot
Study officials:
affiliation: Hospices Civils de Lyon
name: ROUVIERE Olivier, Pr
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rouviere O, Melodelima C, Hoang Dinh A, Bratan F, Pagnoux G, Sanzalone T, Crouzet S, Colombel M, Mege-Lechevallier F, Souchon R. Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study. Eur Radiol. 2017 May;27(5):1858-1866. doi: 10.1007/s00330-016-4534-9. Epub 2016 Aug 23.
Clinical trial NCT00204659: Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Official title: Phase II Study With Rituximab and CHOP in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Primary Gastric Diffuse-Large B-Cell Lymphoma
Keywords: Rituximab
CHOP
DLBCL
gastric lymphoma
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
First posted: 2005-09-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The optimal treatment of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) has not yet been defined. In most circumstances, a stomach-conserving approach is favored, but the role of radiotherapy is still a matter of debate. Recently, Rituximab along with full-dose CHOP chemotherapy has been shown to improve the outcome in elderly patients with nodal DLBCL. However, no data are available with such a therapy in patients with PG-DLBCL. Therefore, in March 2003, we initiated an ongoing, prospective, multicenter phase II study in patients with PG-DLBCL with 6 to 8 cycles of Rituximab (R; 375 mg/m2) plus CHOP-21 in order to evaluate the safety and efficacy of this approach.

Detailed description: see above

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Histologically confirmed primary gastric CD20+ DLBCL
* Written informed consent
* ECOG 0-2

Exclusion Criteria:

* Secondary aggressive Non-Hodgkin's lymphoma involving the gastric area
* HIV positive patients
* Severe organ dysfunction
* Life expectancy of less than 3 months

Primary outcomes:
measure: Complete remission rate
timeFrame: at end of chemo-immunotherapy
measure: Progression-free survival
timeFrame: at 2 and 5 years
Secondary outcomes:
measure: Overall survival
timeFrame: at 2 and 5 years
measure: Toxicity
timeFrame: after chemo-immunotherapy
Other outcomes:
Locations:
city: Augsburg
country: Germany
facility: Zentralklinikum Augsburg
city: Giessen
country: Germany
facility: University of Giessen
city: Reutlingen
country: Germany
facility: Klinikum Reutlingen
city: Tuebingen
country: Germany
facility: University of Tubingen
city: Villingen-Schwenningen
country: Germany
facility: Schwarzwald-Baar Clinic
Study officials:
affiliation: Schwarzwald-Baar Clinic, Academic Teaching Hospital, University of Freiburg
name: Wolfram Brugger, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06100770: Aveir AR Coverage With Evidence Development (CED) Study
Official title: Aveir AR Coverage With Evidence Development (CED) Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cardiac Pacemaker
Arrhythmia
Bradycardia
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2023-10-25
Enrollment: 586
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study cohort will include all Medicare patients with continuous claims data implanted with an Aveir DR leadless pacemaker or a full-system dual-chamber transvenous pacemaker (from any manufacturer) in any US location.

Brief summary: The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the single-chamber Aveir Atrial Leadless Pacemaker device (aka Aveir™ AR LP system).

Detailed description: This CED study utilizes a real-world evidence (RWE) method merging multiple real-world datasets from Abbott and the Center for Medicare Services to assess Aveir AR LP health outcomes among Medicare beneficiaries.

The study will enroll all Medicare patients with continuous claims data implanted with the Aveir AR LP or a single-chamber atrial transvenous pacemaker system from any manufacturer.

Due to the RWE data collection methods used in this study, a central institutional review board (IRB) approved informed consent waiver has been granted. Due to this waiver and the sponsor's use of the central IRB, individual hospitals are not required to consent patients or complete local IRB submissions for this RWE study.

Eligibility criteria: Inclusion Criteria:

1. Medicare beneficiaries implanted with an Aveir AR leadless pacemaker on or after the study start date (i.e., the date of Aveir AR market approval) will be included in the study.

   OR
2. Medicare beneficiaries implanted with a full system (e.g. lead and generator) single chamber atrial transvenous pacemaker on or after the study start date

Exclusion Criteria:

* None

Primary outcomes:
measure: Acute device-related complication rate
timeFrame: 30 days
measure: Two-year survival rate
timeFrame: 2 years
Secondary outcomes:
measure: Chronic complication rate
timeFrame: 6 months
measure: Device related re-intervention rate
timeFrame: 2 years
Other outcomes:
Locations:
city: Sylmar
country: United States
facility: Abbott
state: California
Study officials:
affiliation: Abbott
name: Nicole Harbert
role: STUDY_DIRECTOR
References:
Clinical trial NCT02139670: Thrombin Generation and Gestational Outcome
Official title: Thrombin Generation and Gestational Outcome in Women With Recurrent Pregnancy Loss
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thrombophilia
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2014-05-15
Enrollment: 29
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: pregnant women with recurrent miscarriages undergoing investigation for Thrombophilia .

Brief summary: In total 120 pregnant women's with history of recurrent miscarriages, are planned for inclusion in this trial. After signing an informed consent a blood sample will be obtained from each participant. The investigators will measure the thrombin generation in plasma assessed by the calibrated automated thrombogram (CAT). The relation between pregnancy outcome and thrombin measurements will be determined


Eligibility criteria: Inclusion Criteria:

* age \> 18
* signed inform consent
* first trimester
* two early miscarriages(before week 10) or one later abortions (after week 10)

Exclusion Criteria:

* Chronic treatment with aspirin or other anticoagulants

Primary outcomes:
measure: pregnancy outcome
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Haemek medical center
Study officials:
affiliation: HaEmek Medical Center, Israel
name: mazen elias, prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00813670: Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers
Official title: Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XPF-001 and to Investigate the Effect of Food on the Pharmacokinetics of a Single Dose of XPF-001 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Human Volunteers
Lead sponsor: Xenon Pharmaceuticals Inc.
Sponsor class: INDUSTRY
First posted: 2008-12-23
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single and multiple doses of XPF-001 in healthy volunteers.

The effect of food on the pharmacokinetics of XPF-001 will also be studied.


Eligibility criteria: Inclusion Criteria:

* Healthy subjects (Females of non-childbearing potential) with normal or clinically insignificant laboratory results, ECGs and physical examinations.

Exclusion Criteria:

* Subjects with a presence or history of any clinically significant disease.
* Subjects who have participated in and investigational drug trial within 60 days of admission.
* Subjects who have used tobacco or nictoine products in the 1 month prior to admission
* Females who are pregnant or breastfeeding

Primary outcomes:
measure: ECGs, Telemetry, Vital Signs, Physical Examinations, Laboratory Assessments and Adverse Events.
timeFrame: up to 14 days post dose
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Anapharm
state: Quebec
Study officials:
affiliation: Anapharm
name: Richard Larouche, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01684670: Intensive Dysarthria Sessions in Adults and Children With Down Syndrome
Official title: Intensive Dysarthria Sessions in Adults and Children With Down Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dysarthria
Down Syndrome
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: University of Rhode Island
name: University of Florida
name: University of North Carolina, Chapel Hill
First posted: 2012-09-13
Enrollment: 5
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research study is designed to investigate the feasibility and treatment effects of a behavioral speech treatment in adults and children with Down Syndrome (DS) and dysarthria. The speech sessions will provide an intensive, articulation-based intervention focused on increasing effort during speech production via use of "clear speech." A single subject multiple baselines across subjects design will be employed in a total of six subjects divided into two groups of three. Changes in dependent measures will be determined by visual inspection, effect size determination, and time series analysis. The study follows accepted procedures in rehabilitation treatment and research and there are minimal foreseeable risks associated with participation.


Eligibility criteria: Inclusion Criteria:

* Adults and children with Downs Syndrome and dysarthria
* Ages 8 years and older
* Ability to verbally communicate; follow simple commands and/or imitate others; hear speech at a conversational level; and participate in assessment and speech sessions activities

Exclusion Criteria:

* Additional serious medical problems which prevent meaningful participation in the study.

Primary outcomes:
measure: Speech intelligibility
timeFrame: 3-6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Health System
state: North Carolina
Study officials:
affiliation: Duke University
name: Harrison N Jones, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02066870: Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
Official title: Phase I Study of the Combination of Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Non-small Cell Lung Cancer
Keywords: Icotinib
Arsenic Trioxide
Resistance
Non-small cell lung cancer
Lead sponsor: Betta Pharmaceuticals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2014-02-20
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The NSCLC patients who experienced good clinical responses to an EGFR-TKI will inevitably develop acquired resistance. A great deal of research are focusing on this issue. Arsenic trioxide showed efficacy and safety in acute promyelocytic leukemia, multiple myeloma and other solid tumors. Moreover, preclinical studies showed arsenic trioxide can reduce the resistance of tumor cells to chemotherapy and TKIs.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed stage IIIB/IV lung cancer with EGFR mutation
* Progressed after platinum-based chemotherapy
* The last anti-tumor therapy before entering this study must be gefitinib, erlotinib or icotinib, and the duration for tumor response must be no less than 4 months, or the duration for stable disease must be no less than 6 months
* With a measurable disease with conventional CT) according to RECIST Criteria
* WHO performance status(PS)\<= 2
* N\>=1.5×109/L, Plt\>=1.0×109/L,Hb\>=9g/dL; AST\&ALT should \<2.5ULN(without liver metastasis) or \<5ULN(with liver metastasis).TBIL\<=1.5ULN.
* Signed and dated informed consent before the start of specific protocol procedures.

Exclusion Criteria:

* Allergic to icotinib or arsenic trioxide.
* Patients with metastatic brain tumors with symptoms.
* Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases.

Primary outcomes:
measure: Number of Participants with Serious and Non-Serious Adverse Events
timeFrame: Up to 8 weeks
Secondary outcomes:
measure: Progression-free survival
timeFrame: Up to 4 months
measure: Time to death
timeFrame: Up to 24 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Study officials:
affiliation: Ruijin Hospital
name: Saijuan Chen, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
name: Yuankai Shi, MD
role: PRINCIPAL_INVESTIGATOR
References: